• 1. Dissociation of aryl sulfonyl phthalimide radical anions: relevance to the biological activity of arylsulfonyl amides?
  Abdelaziz Houmam,Emad M. Hamed Chem. Commun., 2012,48, 11328-11330
• 2. Exchangeability of amino acid residues with similar physicochemical properties in coiled-coil interactions?
  Guiying Zhang,Maosheng Cheng,Yanni Li,Keliang Liu,Lifeng Cai Chem. Commun., 2013,49, 11086-11088
• 3. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 4. Evolution study of photo-synthesized gold nanoparticles by spectral deconvolution model: a quantitative approach
  Chung-Sung Yang,Mong-Shian Shih,Fang-Yi Chang New J. Chem., 2006,30, 729-735
• 5. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739

Recent Advances in the Study of 4-Chloro-1H-indazol-7-amine (CAS: 100959-52-2) in Chemical Biology and Pharmaceutical Research

The compound 4-Chloro-1H-indazol-7-amine (CAS: 100959-52-2) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its potential as a versatile scaffold for drug discovery. This heterocyclic amine, characterized by its indazole core and chloro-substitution, has demonstrated promising biological activities, particularly in the modulation of kinase pathways and other critical cellular targets. Recent studies have explored its synthetic accessibility, structure-activity relationships (SAR), and therapeutic applications, making it a focal point for innovative drug development.

One of the key areas of investigation involves the role of 4-Chloro-1H-indazol-7-amine as a building block for kinase inhibitors. Kinases are pivotal in numerous disease pathways, including cancer, inflammation, and neurodegenerative disorders. Researchers have synthesized derivatives of this compound to evaluate their inhibitory effects on specific kinases, such as JAK2 and EGFR. Preliminary results indicate that certain derivatives exhibit nanomolar potency, with improved selectivity profiles compared to existing inhibitors. These findings underscore the potential of 4-Chloro-1H-indazol-7-amine as a lead compound for next-generation kinase-targeted therapies.

In addition to its kinase inhibitory properties, 4-Chloro-1H-indazol-7-amine has been investigated for its utility in fragment-based drug design (FBDD). Fragment-based approaches leverage small, structurally diverse molecules to identify novel binding motifs for target proteins. Recent studies have demonstrated that this compound can serve as a valuable fragment due to its favorable physicochemical properties and ability to form key hydrogen bonds with protein residues. This has led to the discovery of new chemical entities with enhanced binding affinities and reduced off-target effects, highlighting its role in accelerating drug discovery pipelines.

Another notable application of 4-Chloro-1H-indazol-7-amine lies in its incorporation into PROTACs (Proteolysis Targeting Chimeras). PROTACs are bifunctional molecules designed to degrade target proteins by recruiting ubiquitin ligases. Recent research has shown that derivatives of this compound can effectively link E3 ligases to disease-relevant proteins, facilitating their degradation. This approach has shown promise in overcoming drug resistance mechanisms, particularly in oncology, where traditional inhibitors often fail due to mutations or compensatory pathways. The adaptability of 4-Chloro-1H-indazol-7-amine in PROTAC design further expands its therapeutic potential.

Despite these advancements, challenges remain in optimizing the pharmacokinetic and pharmacodynamic properties of 4-Chloro-1H-indazol-7-amine derivatives. Issues such as metabolic stability, solubility, and bioavailability require further investigation to translate these findings into clinically viable candidates. Recent efforts have focused on structural modifications, including the introduction of solubilizing groups and the exploration of prodrug strategies, to address these limitations. Collaborative research between academia and industry is expected to drive progress in this area, paving the way for novel therapeutics.

In conclusion, 4-Chloro-1H-indazol-7-amine (CAS: 100959-52-2) represents a promising scaffold in chemical biology and pharmaceutical research. Its versatility in kinase inhibition, fragment-based drug design, and PROTAC development underscores its broad applicability. Continued research into its SAR and optimization will be critical to unlocking its full potential, offering new avenues for treating complex diseases. This compound exemplifies the intersection of chemistry and biology, serving as a testament to the power of targeted molecular design in modern drug discovery.

• 18259-66-0(4-Amino-6-chlorocinnoline)
• 825654-78-2(1H-Indazol-4-amine, 5-chloro-)
• 100960-35-8(5-Chloro-1H-indazol-6-amine)
• 221681-75-0(6-Chloro-1H-indazol-5-amine)
• 1082041-33-5(4-Chloro-1H-indazol-5-amine)
• 221681-84-1(4-Chloro-1H-indazol-6-amine)
• 187231-27-2(4-Cinnolinamine, 7-chloro-)
• 221681-89-6(7-Amino-5-chloro-1H-indazole)
• 316810-88-5(3-chloro-1H-Indazol-7-amine)
• 885519-32-4(6-Chloro-1H-indazol-4-amine)